228 related articles for article (PubMed ID: 30557411)
1. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
2. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
[TBL] [Abstract][Full Text] [Related]
3. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
4. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
5. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
[TBL] [Abstract][Full Text] [Related]
6. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
[TBL] [Abstract][Full Text] [Related]
7. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
[TBL] [Abstract][Full Text] [Related]
8. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.
Deng T; Pan H; Han R; Huang D; Li H; Zhou L; Wang X; Bai M; Li X; Liu R; Ge S; Ning T; Zhang L; Ba Y
Int J Clin Exp Med; 2014; 7(12):5041-9. PubMed ID: 25664003
[TBL] [Abstract][Full Text] [Related]
10. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B; Stacchiotti S; Collini P; Pantano F; Rabitti C; Perrone G; Iuliani M; Baldi A; Badalamenti G; Sanfilippo R; Santini D; Muda AO; Gronchi A; Casali P; Dei Tos AP; Tonini G
Br J Cancer; 2017 Jul; 117(3):340-346. PubMed ID: 28641307
[TBL] [Abstract][Full Text] [Related]
11. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
[TBL] [Abstract][Full Text] [Related]
12. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
13. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
15. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
16. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
17. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.
Chun JW; Lee B; Park WS; Han N; Hong EK; Park EY; Han SS; Park SJ; Kim TH; Lee WJ; Woo SM
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682775
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
[TBL] [Abstract][Full Text] [Related]
19. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.
Marcé S; Molina-Arcas M; Villamor N; Casado FJ; Campo E; Pastor-Anglada M; Colomer D
Haematologica; 2006 Jul; 91(7):895-902. PubMed ID: 16818276
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Wang H; Word BR; Lyn-Cook BD
Anticancer Res; 2011 Oct; 31(10):3171-80. PubMed ID: 21965724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
